TransCode Therapeutics In... (RNAZ)
NasdaqCM: RNAZ
· Real-Time Price · USD
3.38
-0.05 (-1.46%)
At close: Aug 12, 2026, 11:05 AM
TransCode Therapeutics Inc. (RNAZ) Stock Price, Analysis & Data
-1.46% (1D)
| Bid | 2.48 |
| Market Cap | 3.57M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -43.7M |
| Beta | 1.24 |
| EPS (ttm) | -3.71 |
| PE Ratio (ttm) | n/a |
| Forward PE | -5.62 |
| P/B (ttm) | 2.47 |
| P/S (ttm) | n/a |
| Earnings Date | n/a |
| Ask | 4.39 |
| Volume | 11,840 |
| Avg. Volume (20D) | 62,245 |
| Open | 3.40 |
| Previous Close | 3.43 |
| Day's Range | 3.38 - 3.61 |
| 52-Week Range | 3.38 - 20.99 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About RNAZ
TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising brea...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 8, 2021
Employees 12
Stock Exchange NasdaqCM
Ticker Symbol RNAZ
Financial Performance
In 2025, TransCode Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -34.66M, an increase of 106.87%.
Financial StatementsEarnings Surprise
TransCode Therapeutics has released their quarterly earnings on Apr 15, 2025:
